Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, novembre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
CRISPR Therapeutics AG
CRSP
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$39.10
0.17
0.44%
À la clôture: Nov 20, 4:00 PM EST
$39.50
0.40
1.02%
Après les heures: 7:54 PM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
CRISPR Therapeutics Financials
CRISPR Therapeutics (CRSP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 1.71 percent increase over losses of $(1.17) per share
Benzinga Newsdesk
Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’
Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
Rishabh Mishra
PRO
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of $(2.40) per share
Benzinga Newsdesk
PRO
CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate
Benzinga Newsdesk
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.
Vandana Singh
CRISPR Therapeutics Earnings Report: Q4 Overview
Benzinga Insights